The use of the ancient plant Cannabis sativa for both its medicinal and its psychoactive properties has been known for thousands of years; however, it has only been in the last 20 years that "medical marijuana" (i.e. medical cannabis) regulatory programs have come to the United States. As of the end of 2015, 11 states had passed voter-approved referenda while 12 states and the District of Columbia went through the legislative assembly to establish medical cannabis laws. In addition, an explosion of laws authorizing the use of cannabidiol (CBD) formulations to treat certain medical conditions has occurred in 17 states in the last 2 years alone.
How did this rapid liberalization of state law come about? What does it mean for state economies? What does it mean for patients?
This webinar with expert speaker Erik R. Janus will explain the history of medical cannabis programs in the United States and describe the major state programs and regulatory approaches. The potential for both synthetic and phytocannabinoids to be developed as drugs and used to treat human disease and illness will be discussed, along with research needs and considerations. In addition, the pitfalls that increased cannabis use and exposure have introduced in those states with robust medical and retail markets will be discussed.
This session will describe the use of Cannabis sativa (and synthetic derivatives) as a human and veterinary drug over time, as well as an overview of the current state of affairs in the US. The history of the major state-based medical cannabis regulatory programs will be described, compared and summarized. Plus, the pros (potential) and cons (pitfalls) of using synthetic and phytocannabinoids as medicines will be discussed.
Who Should Attend
This event will be useful for:
Erik R. Janus
Erik R. Janus is the President of M?3; Technical & Regulatory Services LLC, a consulting firm offering technical and analytical services in a wide variety of areas to support the future of chemical risk assessment. Mr. Janus is an environmental health science, risk assessment and regulatory toxicology expert with over ... More info